Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $6.82 million. The enterprise value is $4.96 million.
| Market Cap | 6.82M |
| Enterprise Value | 4.96M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 6.25 million shares outstanding. The number of shares has increased by 130.53% in one year.
| Current Share Class | 6.25M |
| Shares Outstanding | 6.25M |
| Shares Change (YoY) | +130.53% |
| Shares Change (QoQ) | +91.26% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 10.53% |
| Float | 6.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.71 |
| Forward PS | 20.48 |
| PB Ratio | 0.43 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.81 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -174.77% and return on invested capital (ROIC) is -290.60%.
| Return on Equity (ROE) | -174.77% |
| Return on Assets (ROA) | -59.63% |
| Return on Invested Capital (ROIC) | -290.60% |
| Return on Capital Employed (ROCE) | -219.15% |
| Weighted Average Cost of Capital (WACC) | 16.09% |
| Revenue Per Employee | $6,273 |
| Profits Per Employee | -$409,186 |
| Employee Count | 115 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | -1.62M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.13% in the last 52 weeks. The beta is 2.90, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 2.90 |
| 52-Week Price Change | -90.13% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 2.61 |
| Relative Strength Index (RSI) | 45.31 |
| Average Volume (20 Days) | 350,153 |
Short Selling Information
The latest short interest is 304,970, so 4.88% of the outstanding shares have been sold short.
| Short Interest | 304,970 |
| Short Previous Month | 214,608 |
| Short % of Shares Out | 4.88% |
| Short % of Float | 4.97% |
| Short Ratio (days to cover) | 1.15 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $721,386 and -$47.06 million in losses. Loss per share was -$19.36.
| Revenue | 721,386 |
| Gross Profit | 313,634 |
| Operating Income | -30.08M |
| Pretax Income | -48.68M |
| Net Income | -47.06M |
| EBITDA | -29.09M |
| EBIT | -30.08M |
| Loss Per Share | -$19.36 |
Balance Sheet
The company has $3.65 million in cash and $1.80 million in debt, with a net cash position of $1.85 million or $0.30 per share.
| Cash & Cash Equivalents | 3.65M |
| Total Debt | 1.80M |
| Net Cash | 1.85M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 12.71M |
| Book Value Per Share | 2.61 |
| Working Capital | 2.33M |
Cash Flow
In the last 12 months, operating cash flow was -$27.10 million and capital expenditures -$367,372, giving a free cash flow of -$27.47 million.
| Operating Cash Flow | -27.10M |
| Capital Expenditures | -367,372 |
| Depreciation & Amortization | 992,234 |
| Net Borrowing | n/a |
| Free Cash Flow | -27.47M |
| FCF Per Share | -$4.39 |
Margins
| Gross Margin | 43.48% |
| Operating Margin | -4,170.14% |
| Pretax Margin | -6,747.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -130.53% |
| Shareholder Yield | -130.53% |
| Earnings Yield | -671.98% |
| FCF Yield | -392.29% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 357.25% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Co-Diagnostics has an Altman Z-Score of -11.91 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.91 |
| Piotroski F-Score | 3 |